A narrative review of sildenafil dosing and monitoring by indication in neonatal pulmonary hypertension
Abstract
Abstract Pulmonary hypertension in the neonate is a leading contributor to hypoxemic respiratory failure and carries substantial mortality across diverse etiologies, including persistent pulmonary hypertension of the newborn (PPHN), bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH), and the early postoperative course after surgery for congenital heart disease. Congenital diaphragmatic hernia, which frequently involves complex, multifactorial physiology, is considered outside the scope of this review. Inhaled nitric oxide remains the established first-line selective pulmonary vasodilator but is unavailable, ineffective, or impractical in a substantial proportion of clinical scenarios, particularly in resource-limited neonatal units. Sildenafil, an orally and intravenously bioavailable phosphodiesterase type 5 (PDE5) inhibitor, has become the most widely used adjunctive or alternative pulmonary vasodilator in the neonatal intensive care unit, despite remaining off-label for this indication. This narrative review consolidates contemporary, neonatal-specific evidence on the use of sildenafil in newborns and young infants. It focuses on developmental pharmacokinetics, evidence-based oral and intravenous dosing regimens for the principal indications, a structured framework for hemodynamic and echocardiographic monitoring, an indication-stratified clinical algorithm, and the safety profile relevant to this age group. The review also addresses the practical…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.